Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line

This is a non-interventional observational study within the routine chronic myeloid leukemia treatment practice; no further tests were required apart from the assessments routinely performed for Chronic myeloid leukemia patients treated with nilotinib.

Inclusion Criteria:Adult patients diagnosed with Ph+ CML (or evidence of BCR-ABL transcript) treated with nilotinib under routine medical practice and the SmPC, as amended, in first or any subsequent line, if the current therapy with nilotinib has not been in place for more than twelve months. Retrospective documentation of patients for up to one year will be permitted.Patients who have already had an interruption/discontinuation of nilotinib therapy.Patients who have been informed about this NIS and have personally dated and signed their informed consent form.Exclusion Criteria:There are no exclusion criteria, apart from the contraindications mentioned in the SmPC. Participating patients are not allowed to take part in a clinical trial in parallel,